| Number: 201012832 |
Principal Investigator: Bradley, Jeffrey |
| Title: A Phase I/II Trial of Stereotactic Body Radiation therapy (SBRT) Dose Escalation in the Treatment of Patients with Inoperable Stage I/II Non-Small Cell Lung Cancer Arising within the Zone of the Proximal Bronchial Tree |
| Description: The usual treatment for early stage lung cancer is to remove the cancer with surgery. However, when patients have other serious health problems like emphysema, diabetes, or heart disease, they may not be able to have the standard surgery.
Patients who cannot have surgery usually receive radiat...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201209007 |
Principal Investigator: Krupnick, A. Sasha |
| Title: Pulmonary Rehabilitation before Lung Cancer Resection |
| Description: The purpose of this research study is to see how effective a short program (10 sessions) of pre-surgery pulmonary rehabilitation (PR) is on your recovery from the lung cancer surgery....MORE |
| ___________________________________________________________________________________________________ |
| Number: RTOG 1106 |
Principal Investigator: Bradley, Jeffrey |
| Title: Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC) |
| Description: The purpose of this research study is to find out if more intense (higher dose) radiation treatment based on the FDG-PET/CT imaging improves treatment of your cancer with the same possible damage to healthy lung tissue compared to treatment with standard radiation therapy. The higher dose radiation ...MORE |
| ___________________________________________________________________________________________________ |
| Number: RTOG 0937 |
Principal Investigator: Robinson, Clifford |
| Title: Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative extra-cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC) |
| Description: The purpose of this study is to compare the effects, good andlor bad, of radiation given to the brain after chemotherapy to the effects of radiation to the brain, chest and up to 3 other sites (Ie., liver, adrenal
gland, bone, etc..) that did not completely respond to treatment after chemotllerapy ...MORE |
| ___________________________________________________________________________________________________ |
| Number: RTOG 0839 |
Principal Investigator: Robinson, Clifford |
| Title: Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer |
| Description: This study will compare the effects, good and/or bad, of adding panitumumab to chemotherapy and radiation therapy. In this study, you will get chemotherapy and radiation OR radiation, chemotherapy, and panitumumab.
Panitumumab is a drug that may delay or prevent tumor growth by blocking certain cel...MORE |
| ___________________________________________________________________________________________________ |
| Number: CALGB CIRB 30610 |
Principal Investigator: Baggstrom, Maria |
| Title: Phase III Comparison of Thoracic radiotherapy Regimens in Patients with Limited Small Cell Lung cancer also Receiving Cisplatin and Etoposide |
| Description: The purpose of this study is to compare the effects, good and/or bad, of three different ways to give radiation therapy. Two of the ways are experimental, while one of them is standard. The two experimental ways of giving the radiation therapy are (1) once a day with a high dose of radiation for 7 w...MORE |
| ___________________________________________________________________________________________________ |
| Number: CALGB 30801 |
Principal Investigator: Baggstrom, Maria |
| Title: A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer |
| Description: The purpose of this study is to compare the effects, good and/or bad, of adding an experimental drug, celecoxib, to chemotherapy....MORE |
| ___________________________________________________________________________________________________ |
| Number: ACOSOG Z4099 |
Principal Investigator: Crabtree, Traves |
| Title: A Randomized Phase III Study of Sublobar Resection (+/- Brachytherapy) versus Stereotactic Body Radiation Therapy in High Risk Patients with Stage I Non-Small Cell Lung Cancer |
| ___________________________________________________________________________________________________ |
| Number: 201212083 |
Principal Investigator: Baggstrom, Maria |
| Title: LUX-Lung EAP US: An open-label expanded access program of afatinib (BIBW 2992) for patients with locally advanced or metastatic non small cell lung cancer (NSCLC) harboring EGFR mutation(s) |
| Description: The purpose of this study is to provide patients with EGFR positive non-small cell lung cancer with access to afatinib. The study will also look at how well afatinib treats lung cancer and what side effects patients experience....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201212027 |
Principal Investigator: Waqar, Saiama |
| Title: An Open-label, Randomized Phase IIb/III Active Control Study of Second-line HyperAcute®-Lung (tergenpumatucel-L) Immunotherapy versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer |
| Description: The purpose of this study is to assess overall survival of anti-tumor immunization using HyperAcute®-Lung immunotherapy versus Docetaxel in patients with progressed or relapsed non-small cell lung cancer (NSCLC) that have been previously treated....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201212024 |
Principal Investigator: Baggstrom, Maria |
| Title: A phase II, multicenter, single-arm study of oral LDK378 in crizotinib naïve adult patients with ALK-activated non-small cell lung cancer |
| Description: The purpose of this study is to determine whether or not a research drug called LDK378 will help control lung cancer in patients whose lung tumors have a genetic change called an ALK mutation....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201211041 |
Principal Investigator: Baggstrom, Maria |
| Title: A Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC) |
| Description: The purpose of this research study is to look at the safety and tolerability of a drug called AT13387 when given alone or in combination with crizotinib....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201207127 |
Principal Investigator: Waqar, Saiama |
| Title: A Phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV Non Small Cell Lung Cancer |
| Description: The purpose of this study is to learn if the combination of TG4010 (an agent designed to stimulate your own immune system) and standard treatment is more effective than standard treatment alone (for this, the standard treatment will be given in combination with placebo, which is an inactive product ...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201207036 |
Principal Investigator: Govindan, Ramaswamy |
| Title: A Phase II study of the selective BRAF kinase inhibitor GSK2118436 in subjects with advanced non-small cell lung cancer and BRAF mutations |
| Description: The purpose of this research study is to test the safety of the drug GSK2118436 (dabrafenib)
and how well it works and what effects, good or bad, it has on people with non-small cell
lung cancer whose tumors have genetic change called a BRAF mutation....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201205133 |
Principal Investigator: Baggstrom, Maria |
| Title: A Phase 1-2 trial of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non- Small Cell Lung Cancer |
| Description: The main purpose of this study is to learn what the best combined dose of MM-121 is when taken with erlotinib and to find out more about how safe and effective this combination may be as a possible treatment....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201110196 |
Principal Investigator: Waqar, Saiama |
| Title: A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (MetMAb) in Combination with Tarceva; (Erlotinib) in Patients with Met Diagnostic-Positive Non-Small Cell Lung Cancer (NSCLC) who Have Received Standard Chemotherapy for Advanced or Metastatic Disease |
| Description: The purpose of this research study is help to determine whether a humanized antibody (MetMAb) is safe and effective when given to patients with advanced NSCLC in combination with erlotinib, a drug that is commonly used to treat this type of cancer....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201103371 |
Principal Investigator: Baggstrom, Maria |
| Title: Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects with Stage IV/Recurrent Non Small Cell Lung Cancer (NSCLC) |
| Description: The purpose of the study is to determine whether Ipilimumab plus Paclitaxel and Carboplatin will extend the lives of patients with squamous only non small cell lung cancer more than placebo plus Paclitaxel and Carboplatin....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201103359 |
Principal Investigator: Waqar, Saiama |
| Title: An open label two-stage study of orally administered
BKM120 in patients with metastatic non-small cell lung cancer with activated PI3K pathway |
| Description: The purpose of this research study is to find out if the drug BKM120 is safe and has positive effects on patients with non-small cell lung cancer who have progressed after treatment....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102474 |
Principal Investigator: Waqar, Saiama |
| Title: A Phase 1/2 Maximum Tolerated Dose Study of Belinostat (PXD-101) in Combination with Paclitaxel plus Carboplatin in Chemotherapy-Naive Patients with Stage IV Non-Small-Cell Lung Cancer |
| Description: The primary purpose of this research study is to find a safe dose based on side effects of the investigational drug, belinostat, in combination with carboplatin and paclitaxel....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201010738 |
Principal Investigator: Waqar, Saiama |
| Title: Phase 3, Randomized, Open-Label Study of the Efficacy and Safety of Crizotinib versus Pemetrexed/Cisplatin or Pemetrexed/Carboplatin in Previously Untreated Patients with Non-Squamous Carcinoma of the Lung Harboring a Translocation or Inversion Event Involving the Anaplastic Lymphoma Kinase (Alk) Gene Locus |
| Description: The purpose of this research study is to see whether a new investigational drug called crizotinib can keep cancer from growing for a longer period of time compared to the currently available combination of chemotherapy agents pemetrexed/carboplatin or pemetrexed/cisplatin....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201106336 |
Principal Investigator: Puri, Varun |
| Title: Prevention of Postoperative Pneumonia (POPP study)
A study to evaluate the use of a prophylactic clinical strategy to prevent postoperative pneumonia in patients undergoing thoracic surgery |
| ___________________________________________________________________________________________________ |
| Number: 201110272 |
Principal Investigator: Meyers, Bryan |
| Title: Utility of Routine Cervical Mediastinoscopy in Clinically Staged T2N0M0 and Select TIN0M0 Non Small Cell Lung Cancers by FDG-PET and CT scans |
| ___________________________________________________________________________________________________ |
| Number: 201108407 |
Principal Investigator: Bradley, Jeffrey |
| Title: Retrospective Review of Stereotactic Body Radiation Therapy (SBRT) for Cancerous Lesions in the Lung |
| ___________________________________________________________________________________________________ |
| Number: 201202073 |
Principal Investigator: Robinson, Clifford |
| Title: Phase II trial of lithium as a neuroprotective agent for patients with small cell lung cancer (SCLC) treated with prophylactic cranial irradiation (PCI) |
| Description: The purpose of this research study is to see how treatment with lithium carbonate affects your memory when taken before and during PCI, as PCI can lead to the development of short term memory problems. Short term memory is the memory you use to remember lists, like grocery lists. Doctors think peopl...MORE |
| ___________________________________________________________________________________________________ |
| Number: RTOG 1012 |
Principal Investigator: Robinson, Clifford |
| Title: Phase II Randomized Trial of Prophylactic Manuka Honey for the Reduction of Chemoradiation Therapy Induced Esophagitis- Related Pain During the Treatment of Lung Cancer |
| Description: The purpose of this study is to compare the effects, good and/or bad, of standard supportive care with honey on you and your esophagitis-related pain to find out which is better. In this study, you will get either the standard supportive care or the honey. However, if you receive the honey and it do...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201301108 |
Principal Investigator: Mardis, Elaine |
| Title: The Genomics of Acquired Resistance in Non-Small Cell Lung Cancer (NSCLC) |
| ___________________________________________________________________________________________________ |
| Number: 201110275 |
Principal Investigator: Krupnick, A. Sasha |
| Title: Immunoregulation of Lung Cancer by Natural Killer Cells |
| Description: This study is not a treatment trial.
The purpose of this research study is to investigate the differences in “natural killer” (NK) blood cells, a type of white blood cell that fights infection in the body, among different types of patients that have lung surgery.
This study consists of a one-time ...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201108108 |
Principal Investigator: Govindan, Ramaswamy |
| Title: Tissue Acquisition for Analysis of Genetic Progression Factors in Neuroendocrine Tumors |
| Description: The purpose of the project is to discover genetic changes associated with small cell lung cancer and other neuroendocrine tumors. This should lead to better ways to prevent, detect, and treat small cell lung cancer and, perhaps, other diseases as well....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201105020 |
Principal Investigator: Anadkat, Milan |
| Title: Retrospective and Prospective Data Collection and Analysis of Cutaneous Chemotherapy REACTions at Washington University |
| ___________________________________________________________________________________________________ |
| Number: 201012756 |
Principal Investigator: Govindan, Ramaswamy |
| Title: Tissue Source Site (TSS) Network for the Cancer Genome Atlas Project (TCGA) |
| ___________________________________________________________________________________________________ |
| Number: 201102237 |
Principal Investigator: Govindan, Ramaswamy |
| Title: Analysis of Genetic Progression Factors in Lung Cancer
-Consent to use stored tissue specimen
|
| Description: The purpose of the project is to discover genetic changes associated with lung cancer. This should lead to better ways to prevent, detect, and treat lung cancer and, perhaps, other diseases as well....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201302014 |
Principal Investigator: Puri, Varun |
| Title: National Cooperative Group Trials of “High-risk” Patients with Lung Cancer: Are They Truly “High-risk”? |
| ___________________________________________________________________________________________________ |
| Number: 201208142 |
Principal Investigator: Puri, Varun |
| Title: Predictive Models in Lung Cancer - A Retrospective Institutional Study |
| ___________________________________________________________________________________________________ |
| Number: 201206137 |
Principal Investigator: Puri, Varun |
| Title: A study to establish incidence, risk factors, and consequences of postoperative pneumonia after major thoracic surgery |
| ___________________________________________________________________________________________________ |
| Number: 201112048 |
Principal Investigator: Bernadt, Cory |
| Title: Utilization of Cytology Specimens to Identify EGFR and KRAS Mutations in Primary Lung Adenocarcinomas Using Next-Generation Sequencing Technology |
| ___________________________________________________________________________________________________ |
| Number: 201108327 |
Principal Investigator: Wang-Gillam, Andrea |
| Title: Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies |
| Description: The purpose of this study is to determine the maximum tolerated dose and side effects of the combination of two drugs, temsirolimus and erlotinib, used to treat solid tumor cancers. Temsirolimus is approved by the Food and Drug Administration (FDA) for treatment of renal cancer and is considered inv...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201107068 |
Principal Investigator: Lockhart, A. Craig |
| Title: Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients with Varying Degrees of Hepatic Impairment |
| Description: The purpose of this study is to determine if Cabazitaxel is a safe treatment for patients with advanced cancers of different types who also have different levels of liver dysfunction. The highest safe dose of cabazitaxel (the maximum tolerated dose, or MTD) that can be given to patients with your le...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102468 |
Principal Investigator: Lockhart, A. Craig |
| Title: An Open-Label Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 When Administered as a Single Agent in Patients With
Advanced or Metastatic Solid Tumors |
| Description: There are two parts to this research study. The purpose of Part 1 is to find out the highest safe dose of the investigational drug CEP-9722. “Investigational” means that the study drug has not been approved by the United States Food & Drug Administration (F.D.A). Part 2 of the study is to find out m...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102462 |
Principal Investigator: Lockhart, A. Craig |
| Title: A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects with Advanced Solid Malignancies |
| Description: The main purpose of this study is to find out if the drug ZSTK474 is safe in people who have advanced cancers.
ZSTK474 is an investigational (experimental) drug. This means it has not been approved by the Food and Drug Administration (FDA). It is not currently on the market in any country. This stu...MORE |
| ___________________________________________________________________________________________________ |